Inflarx NV (NASDAQ:IFRX) Receives $6.20 Average Target Price from Analysts

Share on StockTwits

Inflarx NV (NASDAQ:IFRX) has received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.20.

IFRX has been the topic of several analyst reports. Raymond James reissued a “hold” rating on shares of Inflarx in a research note on Friday, July 19th. Zacks Investment Research cut Inflarx from a “hold” rating to a “sell” rating in a research note on Thursday, August 15th. Guggenheim cut Inflarx from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $65.00 to $6.00 in a research note on Wednesday, June 5th. Svb Leerink cut Inflarx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 5th. Finally, SunTrust Banks cut Inflarx from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $55.00 to $5.00 in a research note on Wednesday, June 5th.

NASDAQ IFRX traded down $0.07 during trading hours on Friday, hitting $2.83. 4,646 shares of the company were exchanged, compared to its average volume of 526,062. The stock has a 50-day moving average price of $2.81 and a 200 day moving average price of $22.02. Inflarx has a 52 week low of $2.45 and a 52 week high of $53.10. The stock has a market cap of $75.28 million, a PE ratio of -2.04 and a beta of -1.49.

Inflarx (NASDAQ:IFRX) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.11). As a group, analysts expect that Inflarx will post -2.25 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Inflarx during the second quarter valued at approximately $445,000. Spark Investment Management LLC bought a new position in shares of Inflarx during the first quarter valued at approximately $359,000. Atria Investments LLC bought a new position in shares of Inflarx during the second quarter valued at approximately $297,000. Victory Capital Management Inc. bought a new position in shares of Inflarx during the first quarter valued at approximately $3,094,000. Finally, Alpine Global Management LLC bought a new position in shares of Inflarx during the second quarter valued at approximately $95,000. 17.06% of the stock is currently owned by hedge funds and other institutional investors.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Article: Limitations of analyzing profit margin

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.